Mayne Pharma Group has the GF Score of 48, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Mayne Pharma Group
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Mayne Pharma Group (ASX:MYX) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Mayne Pharma Group GF Score Related Terms
ASX:MYX vs MCK, CAH, COR: GF Score Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group GF Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's GF Score distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's GF Score falls into.
Mayne Pharma Group (ASX:MYX) has a GF Score of 48 as of Jul. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Mayne Pharma Group and its competitors. This is near median its historical median of 52.00. Over the past decade, Mayne Pharma Group's GF Score has ranged from 36.00 to 82.00.
Is Mayne Pharma Group's GF Score too high?
Mayne Pharma Group's current GF Score of 48 is near median its 10-year median of 52.00. Over the past 10 years, this metric has ranged from a low of 36.00 to a high of 82.00. Overall, Mayne Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's GF Score compare to MCK and CAH?
Mayne Pharma Group's GF Score of 48 can be compared against companies in the Medical Distribution industry. Historically, Mayne Pharma Group's own GF Score has ranged from 36.00 to 82.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Distribution company?
A good GF Score depends on the Medical Distribution industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Mayne Pharma Group and its competitors. Mayne Pharma Group's current GF Score is 48, which is near median its own 10-year median of 52.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.32, compared to a current price of A$2.78 — trading 47.7% below its estimated fair value. The current GF Score is 48, which is near median its 10-year median of 52.00. Mayne Pharma Group's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current GF Score is 48 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.78 is trading 47.7% below its estimated GF Value™ of A$5.32.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
GF Score: 48 (near median its 10-year median of 52.00)
GF Value™: A$5.32 vs. price of A$2.78 (47.7% below fair value)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
48GF Score
Get the complete analysis for ASX:MYX
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 